Table 2B.

Predictors for Local-Regional Failure with cCRT and Durvalumab

	Univariate
	HR (95% CI)	p - value
Age	1.0 (0.93 – 1.07)	0.98
Sex	1.03 (0.33 – 3.26)	0.96
ECOG 0 vs ECOG 1	0.91 (0.27 – 3.04)	0.88
Histology*	1.76 (0.56 – 5.56)	0.33
Gross Tumor Volume	1.003 (0.99 – 1.01)	0.15
Stage IIIC vs IIIA/IIIB	1.46 (0.39 – 5.41)	0.57
KRAS mt	1.23 (0.37 – 4.14)	0.73
KEAP1/STK11/PBRM1/SMARCA4 CoMt	0.78 (0.17 – 3.58)	0.75
KEAP1/NFE2L2 mt	1.45 (0.44 – 4.83)	0.56
PD-L1 ≥ 50%	1.07 (0.29 – 4.05)	0.96
PD-L1 ≥ 1%	1.05 (0.31 – 3.59)	0.94
Time to Durvalumab Start	0.82 (0.41 – 1.66)	0.54

^*Adenocarcinoma vs Squamous/Other